Experimental antiviral drug shows promise in treating COVID-19


A preliminary study shows that molnupiravir, an experimental antiviral drug, significantly reduced infectious virus in COVID-19 patients after five days of treatment.
The drug is being developed by Ridgeback Biotherapeutics and Merck, with the companies sharing the study's results on Saturday. Testing is ongoing, and if further results show the drug can treat COVID-19 patients exhibiting symptoms, it could be the first oral antiviral used to fight the disease, The Wall Street Journal reports.
The preliminary results are from a Phase 2 trial, which studied the effect of different doses in 182 people who had first reported COVID-19 symptoms within the previous week, tested positive during the most recent four days, and were not hospitalized. After five days, tests were unable to detect infectious virus in volunteers who took molnupiravir twice a day. Among those who received placebos, infectious virus was found in 24 percent of participants. The study also found that after three days, volunteers who took larger doses had lower levels of infectious virus than those who took the placebo.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, told the Journal the study is "tantalizing and interesting, but it's not exactly 100 percent complete. What we need to confirm is that there's clinical benefit." So far, the only antiviral that has been authorized for use in COVID-19 patients is remdesivir, which studies have found modestly benefits hospitalized patients by shortening their stays.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
June 29 editorial cartoons
Cartoons Sunday's political cartoons include the AI genie, Iran saving face, and bad language bombs
-
A tall ship adventure in the Mediterranean
The Week Recommends Sailing aboard this schooner and exploring Portugal, Spain and Monaco is a 'magical' experience
-
How drone warfare works
The Explainer From Ukraine to Iran, it has become clear that unmanned aircraft are rapidly revolutionising modern warfare
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia